Premature aging in childhood cancer survivors (Review)

JARMILA KRUSEOVA, ANDREA ZICHOVA and TOMAS ECKSCHLAGER

Department of Pediatric Hematology and Oncology, 2nd Medical Faculty,
Charles University and University Hospital Motol, 150 06 Prague, Czech Republic

Abstract. Progress in medicine has increased the survival time of children suffering from cancer; >80% of patients survive for at least 5 years from the end of treatment. However, there are late effects of anticancer therapy, which accompany this success. Two-thirds of childhood cancer survivors (CCSs) have at least one late effect (any side effects or complications of anticancer treatment that appear months to years after the completion of treatment), e.g. endocrinopathies, cardiovascular diseases or subsequent cancers, and half of these late effects are serious or life threatening. These late consequences of childhood cancer treatment pose a serious health, social and economic problem. A common mechanism for developing a number of late effects is the onset of premature biological aging, which is associated with the early onset of chronic diseases and death. Cellular senescence in cancer survivors is caused by therapy that can induce chromosomal aberrations, mutations, telomere shortening, epigenetic alterations and mitochondrial dysfunctions. The mechanisms of accelerated aging in cancer survivors have not yet been fully clarified. The measurement of biological age in survivors can help improve the understanding of aging mechanisms and identify risk factors for premature aging. However, to the best of our knowledge, no single marker for the evaluation of biological or functional age is known, so it is therefore necessary to measure the consequences of anticancer treatment using complex assessments. The present review presents an overview of premature aging in CCSs and of the mechanisms involved in its development, focusing on the association of senescence and late effects.

Contents

1. Introduction

Owing to improvements in the diagnostics and treatment of childhood cancer, >80% of patients are cured (1). However, childhood cancer survivors (CCSs) are at risk of developing late effects (any side effects or complications of anticancer treatment that appear months to years after the completion of treatment). Approximately two-thirds of CCSs have at least one late effect of anticancer therapy, and nearly half of these late effects are serious or life threatening (1-4). Late effects can affect any organ or tissue and can occur at different time intervals after treatment (early, <5 years; late, 5-20 years; very late, >20 years) (5,6). Given the high number of CCSs (>500,000 in Europe in 2020) (1), these late effects are not only a medical, but also a social and economic problem.

2. CCSs and late effects

Several studies have already shown that numerous diseases develop much earlier in patients after cancer treatment compared with development in the general population (7-9). For example, at 20 years of age, CCSs have the same risk of developing a chronic disease as their siblings at 50 years of age (8). These patients are three times more likely to develop chronic diseases (e.g., subsequent neoplasms, cardiovascular diseases and endocrinopathies) compared with a control group of their siblings (8,9). In our recent study on CCSs (10), ultrasound sporadic renal angiomyolipomas were detected much earlier in CCSs (median age at diagnosis, 27.9 years) compared with that reported in the general population (50-60 years).

At 45 years of age, 95% of patients in remission have at least one chronic health problem (11). Late effects can be divided according to the type of organ or system disability and according to the type and extent of anticancer and/or supportive therapy used. Late effects can affect any organ or system (e.g., endocrine, cardiovascular, kidney, lung, gastrointestinal, hearing, eye, skin, neurocognitive and locomotor disorders), the most common of which are endocrinopathies, with the most severe, often lethal, including cardiovascular

Correspondence to: Professor Tomas Eckschlager, Department of Pediatric Hematology and Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol, V Uvalu 84, 150 06 Prague, Czech Republic
E-mail: tomas.eckschlager@lfmotol.cuni.cz

diseases and subsequent cancers (1-4,12,13). Psychosocial consequences, which are often caused or increased by somatic damage, are also very important for the quality of life (1). Late effects therefore need to be investigated to elucidate their mechanisms; this will contribute to reducing late effect incidence rates and improving and individualizing screening.

A common mechanism of late effects is the premature biological aging of the individual. Biological aging is a heterogeneous process; it does not undergo the same rate of chronological aging and is the basis for the loss of physiological functions of the body and the increase in aging-related diseases over time (14,15). Biological aging is associated with the early onset of chronic diseases and leads to a higher risk of premature death of patients compared to the general population (8). Research has shown that cancer treatment leads to accelerated aging, which manifests as an increased risk of subsequent neoplasms or cardiovascular diseases in CCSs and in adult cancer survivors (16). Stelwagen *et al* (17) demonstrated that long-term testicular cancer survivors treated with cisplatin had accelerated vascular aging (increased vascular stiffness, increased ischemic and recovery time on digital cooling tests, and albuminuria), and Zhu *et al* (18) found the frequent appearance of aging-related conditions in breast cancer survivors. In another study, long-term childhood acute lymphoblastic leukemia (ALL) survivors demonstrated a late mortality that was more than three times higher than in the age-matched US population (19). In a study by Bøhn *et al* (20), one out of four long-term survivors of adolescent and young adult (AYA) cancer complained of chronic fatigue, and in a multicenter study in the UK (21), 85% of AYA cancer survivors complained of chronic fatigue 1 year after finishing therapy. The differences between these data are likely due to the method of evaluation and on the population of survivors themselves.

3. Cell senescence

Cellular senescence serves an important role in aging; it is a process of permanent cell cycle arrest and involves the induction of specific phenotypic changes (22). Senescent cells stop dividing, enter the G0 phase and remain metabolically active (22). As cells undergo senescence in response to various stress stimuli, the whole process of senescence can be understood as a defense mechanism of the organism to prevent further growth of damaged cells (22,23).

There are two known pathways of cellular senescence: Replicative and premature/accelerated senescence. The observation that cells grown *in vitro* divide ~50 times and then stop dividing has led to the description of replicative senescence (24). This senescence is caused by telomere shortening (25). Premature/accelerated cellular senescence is independent of the length of the telomeres; in this pathway, cells respond to various negative stimuli such as oxidative stress or DNA damage (23). The difference between replicative and accelerated senescence is only in the stimulus to which the cells respond, its reaction is the same in both cases (23). When cell senescence is in response to a DNA-damaging stress stimuli, cells that are unable to undergo senescence and apoptosis due to mutations in genes important for their induction

(e.g., p14^{ARF}, p16^{INK4}, RB1 and p53 pathways) will still divide and their daughter cells will suffer the same damage (26,27).

Several mechanisms [such as, epigenetic changes, accumulation of mutations, including mutations of mitochondrial DNA (mtDNA), and depletion of stem cells] contribute to aging and the development of aging-related diseases. Epigenetic changes include the accumulation of histone variants and aberrant histone modifications, changes in the accessibility of chromatin and deregulated expression of some microRNAs [e.g. expression of miR-99b-5p, miR-130b-5p, miR-505-5p and miR-425-3p are negatively associated with age (28)] that cause changes in gene transcription (29). The accumulation of mutations throughout life contributes to the biological changes that accompany aging (30), which may explain the increased risk of subsequent cancer and accelerated aging in CCSs (31). Mitochondrial genomes display a higher mutation rate compared with somatic genomes and are more sensitive to the genotoxic effects of anticancer therapy (32). mtDNA mutations can damage the mitochondria and thus reduce the ability of muscle cells to regenerate, which is one of the signs of old age (33). Stem cell compartments are depleted with age (34,35), but these cells can also undergo an accelerated aging process (36,37).

4. Biological age and its measurement

Biological age. To estimate accelerated aging in cancer survivors, the term called biological age was introduced, which predicts the risk of late effects more precisely than does chronological age (16). However, the assessment of biological age is difficult, and there is no consensus on its methodology. The so-called aging clocks are a set of signs that can predict biological age; epigenetic and proteomic aging clocks have been developed. The functional status and incidence of chronic diseases and geriatric syndromes can also be used to assess biological age (38).

Epigenetic clocks. Epigenetic clocks use markers based on different levels of CpG site methylation (e.g., Horvath's clock based on 353 CpG sites and Hannum's clock based on 71 CpG sites) detected in blood or tissues (39,40); results of these two clocks correlated with chronological age in relatively healthy individuals (39,40). Subsequently, Horvath's group developed another aging clock based on methylation (41). In the development of this clock, not only chronological data were used, but predictors of phenotypic age (for example, age at menopause, decline of the immune system and aging-related morbidity) were also taken into account. Therefore, it was assumed that this clock would better correlate with biological age, life expectancy and the incidence of aging-related diseases (41,42). Several other epigenetic clocks have been described (16). Furthermore, the methylation of some genes, including ELOVL2, FHL2 and PENK, have been shown to correlate well with biological age (43).

Several studies have found a correlation between an increased risk of cancer and biological age in the general population. Zheng *et al* (44) measured epigenetic age using Horvath's method and observed that an increase in epigenetic age was associated with an increased risk of developing any cancer within 3 years. In another study, Levine *et al* (45) found

that a 1-year increase in biological age measured by Levine's clock (based on methylation of 513 CpG sites) was associated with a 5% increase in the risk of lung cancer. Acceleration of biological age measured using Levine's clock was associated with an increased risk of invasive breast cancer, particularly in postmenopausal women (46). However, other studies have provided conflicting results. For example, an EPIC-Italy study found that men had a biological age-associated risk of colorectal cancer according to Horvath's clocks and the methylation levels of FHL2 CpG islands, but not according to Hannum's or Weidner's clocks, or according to the methylation levels of ELOVL2 CpG islands (47). In that study, an association with ELOVL2 methylation and breast cancer occurrence was observed in women, but no associations between any of the five clocks tested and colorectal cancer risk in women was found.

Only a limited number of studies have followed the epigenetic age of CCSs. Epigenetic age acceleration (EAA) evaluated by Levine's clock increased in CCSs compared to controls (48). Higher EAA was observed particularly after chest, abdominal or pelvic radiotherapy, or after alkylating agent, glucocorticoid or epipodophyllotoxin therapy. Acceleration was also associated with hypertension, myocardial infarction, obesity, peripheral neuropathy and pulmonary obstruction or diffusion deficits (48), and EAA could be partly influenced by the lifestyle of survivors (for example, participating in physical activity, alcohol consumption and smoking) (48).

Proteomic aging clocks. Proteomic aging clocks are based on aging-related biomarkers in the blood measured using proteomic methods. Johnson *et al* (49) developed two versions of the proteomic aging clock: A 23-protein panel and an 83-protein panel. Both panels showed good correlations with chronological age. Tanaka *et al* (50) identified >200 proteins that are associated with age and developed a proteomic age clock that used only eight of those proteins, which correlated well with the chronological age of controls.

Markers of cell aging. To date, several markers of cell aging have been identified, such as p16[INK4a], p16[ARF], senescence-associated β-galactosidase, hyperphosphorylation of Rb1 and the levels of certain cytokines including, IL-6 and IL-8 (51-53). A case-control study found that an increase in p16[INK4a] expression in peripheral blood T-lymphocytes was associated with an increased risk of breast cancer (54). Sanoff *et al* (55) demonstrated that the expression of p16[INK4a] and ARF in peripheral blood T-lymphocytes increases immediately after chemotherapy and remains high for at least 1 year after treatment. This increase corresponded to ~15 years of chronological aging. Cellular age evaluated in terms of p16[INK4a] expression in peripheral blood T-lymphocytes was found to be >2 decades higher than chronological age in CCSs and AYA cancer survivors. Furthermore, 'frail' survivors had higher expression levels of p16[INK4a] than did 'non-frail' survivors (56). Higher expression levels of p16[INK4a] has also been associated with higher doses of chemotherapy prior to transplantation and with autologous hematopoietic stem cell transplantation (HSCT) in adult cancer survivors (57). The expression of p16[INK4a] in peripheral blood T-lymphocytes was higher in adult survivors of testicular germ cell cancer (both seminoma and non-seminoma) treated by chemotherapy compared with that in the matched controls (58). To the bets of our knowledge, similar information is not available for CCSs.

5. Premature aging in cancer survivors

One of the important signs of aging is frailty; for example, sarcopenia, decreased muscle strength, poor endurance, slow walking speed and low physical activity (59-61). Frailty was found in ~8% of CCSs who were >10 years post-cancer diagnosis and in their fourth decade of life (59). This increased to ~60% in older survivors of adult cancer who were >70 years old (60), whereas prevalence of frailty was ~10% in adults >65 years in various European, American and Asian populations (61). Frailty among cancer survivors is associated with a higher incidence of chronic diseases and mortality (62). A recent St. Jude lifetime cohort study showed that frailty in young adult cancer survivors is associated with decline in cognitive functions (63). The prevalence of frailty also depends on methodology (e.g., questionnaire, clinical examination and exercise testing) and on the definition of frailty itself (61,64). Childhood patients of brain tumors, bone tumors and Hodgkin lymphoma (HL) are at the highest risk of frailty (59,64). Brain, abdominal and pelvic irradiation, platinum cytostatic chemotherapy, HSCT, limb amputation and lung operations are also factors in the increased risk of frailty in CCSs (59,64,65). Female CCSs are frequently more frail than male CCSs (59,64). This can be partially explained by the sex-dependent acute toxicity of some cytostatics and their late effects (66). Furthermore, in the non-cancer population, frailty is more common in women than in men, which is thought to be due to the lower amount of muscle mass in women (61). Anticancer therapy-associated risk factors may be potentiated by lifestyle, such as smoking, obesity and low physical activity (59,64,67-69).

Osteoporosis and sarcopenia are additional signs of premature aging in CCSs. Decreased bone mineral density is common in CCSs (occurring in 9-18% of patients) and risk factors include ALL, brain tumors, HSCT, glucocorticoid therapy, radiation therapy, malnutrition and hypogonadisms and/or growth hormone deficiency (70). In two studies, Lee and Kim (71) and Lee *et al* (72) described an increased risk of cardiovascular diseases in male adult cancer survivors with sarcopenia, compared with those without and an almost three times higher risk of metabolic syndrome in both adult male and female survivors with sarcopenia.

Plasma levels of CRP, IL-1β, IL-6, advanced glycation end products (AGE) and the reduced/oxidized glutathione ratio were significantly higher in childhood HL survivors than in the matched controls (73). AGE accumulation leads to the subsequent activation of AGE receptors and the activation of intracellular pro-inflammatory signaling (73). These findings indicate that signs of inflammation and activation of antioxidant enzymes are one of the factors that contribute to aging, and may serve an important role in the development of late effects in CCSs (73). AGE are also responsible for alteration of the function and/or structure of secreted proteins, including fibrinogen, collagen and low-density lipoproteins (74).

Inflammation activates two important cytotoxic mediators, reactive oxygen species (ROS) and reactive nitrogen species (RNS), which damage cellular DNA (75). ROS

and RNS induce the production of cytokines and adhesion molecules and activate lymphocytes (76). Subsequently, this induces a chronic systemic inflammatory response known as 'inflamm-aging', which damages tissues by this increase in cytokines and activated lymphocytes (77). Inflamm-aging can involve any organ or tissue and is responsible for the development of osteoporosis, infertility, and metabolic and cardiovascular diseases (78). Metabolic syndrome occurs in about one in three CCSs, but its incidence can be influenced by lifestyle (79). Several studies have focused on the association of variants of different genes with metabolic syndrome in CCSs (80,81). Only one of these CCS studies observed a correlation between variants of the leptin receptor gene and obesity in women, especially those exposed to cranial irradiation, but no correlation was observed in men (81). The association of obesity with brain irradiation may suggest that growth hormone deficiency is involved in the development of metabolic syndrome (81). As such, it seems that in addition to genetic influences, several other factors serve roles in the development of metabolic syndrome in CCSs; however, further studies are necessary for clarification.

Peripheral blood mononuclear cells from CCSs showed less efficient oxidative phosphorylation, increased lipid peroxidation and increased lactate fermentation compared to matched controls (82). The age prediction model based on modifications of glucose catabolism in mononuclear cells showed that the predicted ages were higher compared with the actual ages; by contrast, the predicted ages of healthy controls were not very different from their actual ages (82).

Several studies in women (including prepubertal girls, AYA and in older premenopausal women) treated with chemotherapy showed decrease in anti-Müllerian hormone (AMH) levels during chemotherapy (83-85). Recovery of AMH levels was variable and, in some cases, low levels persisted. AMH levels provide information about ovarian reserve and may be a marker of ovarian aging (86). Female CCSs with a heterozygous genotype of rs1172822 in the BRSK1 gene had an increased risk of low AMH value. BRSK1 is thought to affect the secretion of gonadotropin-releasing hormone from the hypothalamus (87). Variants of cytochrome P450 (CYP450) enzymes that are important in drug metabolism affect the decrease in AMH levels in CCSs. For example, the CYP3A4[*]3 variant is associated with lower AMH levels, whereas CYP2B6[*]2 has a protective effect on the ovaries, which was manifested by higher AMH levels (88).

6. Mechanisms of premature senescence in CCSs

Premature aging in cancer survivors is caused by several mechanisms both at the cellular level and at the level of the whole individual. Cellular senescence in cancer survivors can be caused by chemotherapy, which may induce structural chromosomal aberrations, aneuploidy, polyploidy and endoreduplication, and/or by ionizing radiation, which generates single and double-strand DNA breaks. Studies detecting chromosomal abnormalities in the lymphocytes (89,90) and telomere shortening (65,75,91) in CCSs have been published. Childhood HL male survivors had a higher frequency of chromosomal breaks and gross chromosomal rearrangements that were random and complex compared with the healthy controls. This is consistent with genomic instability (89). Smith *et al* (90) detected a higher occurrence of translocation involving chromosome 4 in childhood and young adult HL survivors. The frequency of translocations was not significantly different between the group treated by radiation only and the group treated by combination of radiation and chemotherapy, but the latter group had a higher frequency of translocations (90). The CCSs of high-risk neuroblastoma (65), ALL (75) and a large group (2,427 CCSs) with different childhood cancers that included leukemias, lymphomas and solid tumors (91) had significantly shorter telomere length than the age- and sex-matched controls.

Another mechanism involved in the induction of cell senescence is epigenetic changes. Different patterns of DNA methylation were described in peripheral leukocytes from AYA HL survivors and from their unaffected twins (92). Daniel *et al* (76) observed altered DNA methylation in genes for immune response, inflammatory processes and oxidative stress in CCS T-cells >10 years after patients were treated with total body irradiation and HSCT.

Lipshultz *et al* (93) reported mitochondrial dysfunction as one of the signs of cell senescence in CCSs. The authors detected a higher mtDNA copy number per cell in childhood ALL survivors exposed to doxorubicin compared with those exposed to doxorubicin along with the cardioprotective dexrazoxane. Dexrazoxane acts by decreasing the formation of superoxide, and the authors suggested that this may represent persistent mitochondrial clonal expansion in response to early damage during doxorubicin administration, and dexrazoxane prevented doxorubicin-induced cardiac mitochondrial dysfunction by protecting oxidative phosphorylation activities and mtDNA integrity (93).

Another mechanism involved in premature aging in survivors is changes affecting the integrity of the entire individual, such as with endocrinopathies. For example, growth hormone deficiency was found in 12.5% of CCSs and in 46.5% of CCSs after radiotherapy involving the hypothalamic-pituitary region (70). This hormonal deficiency induces dysfunction in the insulin and insulin-like growth factor signaling pathway and the ability of cells to detect glucose, which is associated with increased risk of mortality and cardiovascular morbidity (62). Furthermore, luteinizing hormone/follicle stimulating hormone deficiency may participate in the premature aging reported in 6.5% of CCSs (70). The main risk factors are damage to the hypothalamic-pituitary region by a tumor, surgery and/or radiotherapy.

Other late effects in CCSs that mimic senescence are cognitive defects. These include, processing speed and executive functions, but attention and memory may also be affected (94). The risk factors for cognitive defects are a younger age at diagnosis, female sex and brain irradiation (94). Cognitive defects are accompanied by structural changes in the brain. Armstrong *et al* (95) described the correlation of memory impairment with decreased temporal lobe volume, white matter defects and changes of blood oxygen-dependent signaling in the hippocampus of survivors of childhood ALL after 24 Gy cranial radiotherapy but not at lower doses. Cerebrovascular dysfunction, and cardiac and pulmonary late effects can also be involved in cognitive defects through altered organ perfusion and hypoxia in childhood HL survivors (96).

7. Conclusions and future directions

Taken together, these studies indicate that anticancer therapy accelerates aging. However, the mechanisms of accelerated aging in cancer survivors are not yet fully understood. Measuring biological age in CCSs can help to improve the understanding of the biological mechanism of aging and to identify risk factors for premature aging. However, to the best of our knowledge, no single marker is currently known to assess biological or functional age. Therefore, a multilevel approach is needed to measure the aging-related consequences of anticancer therapy (97).

Owing to the increasing number of cancer survivors at risk of accelerated aging, the National Cancer Institute (US National Institutes of Health) organizes think tanks to design perspective strategies to prevent, slow or reverse the aging consequences of cancer and its treatment (98). To develop research on the late effects of CCSs, prepare guidelines for patient follow-up, spread awareness of CCS issues and enable CCSs to actively participate in care, PanCare was established (https: //www.pancare.eu). PanCare is a European network of experts, former pediatric cancer patients and their families, which aims to ensure that every cancer patient diagnosed in childhood and adolescence is provided with optimal long-term care after treatment. The PanCare project creates a common European platform for the care of this growing group of former pediatric oncology patients and for research projects in this area (99). PanCare studies also focus on understanding the risk of developing subsequent tumors and the risk of late mortality and morbidity in CCSs (100,101).

The present review summarizes the role premature aging plays in the development of late effects. Additional studies are needed not only to understand premature aging in CCSs but also how to prevent it. Aging-related consequences of cancer treatments would lead to anti-aging prevention and therapy. Physical training has been described to improve signs of frailty in CCSs (102). However, more data are needed to prepare training programs suitable for cancer survivors. It has been known for almost a century that caloric restriction prolongs life and delays aging-related pathology in laboratory animals (103). Evolutionarily conserved signaling pathways, such as mTOR, appear to mediate the anti-aging effects of diets, and the study of these pathways has contributed to the finding of molecular targets for pharmacological interventions (104). However, the suitability of these diets in cancer survivors for the prevention of accelerated aging is unclear.

Acknowledgements

Not applicable.

Funding

Availability of data and materials

Not applicable.

Authors' contributions

TE designed the review and completed the manuscript. JK and AZ performed the literature search and drafted the manuscript. All authors have read and approved the final version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagranda L, Grabow D, Grootenhuis M, Kaatsch P, Kaiser M, et al: Health-related quality of life in european childhood cancer survivors: Protocol for a study within PanCareLIFE. JMIR Res Protoc 10: e21851, 2021.
2. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL and Mertens AC: Late mortality among 5-year survivors of childhood cancer: A summary from the childhood cancer survivor study. J Clin Oncol 27: 2328-2338, 2009.
3. Bhuller KS, Zhang Y, Li D, Sehn LH, Goddard K, Mcbride ML and Rogers PC: Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: Report of the childhood/adolescent/young adult cancer survivors research program and the BC cancer agency centre for lymphoid cancer. Br J Haematol 172: 757-768, 2016.
4. Oeffinger KC and Hudson MM: Long-term complications following childhood and adolescent cancer: Foundations for providing risk-based health care for survivors. CA Cancer J Clin 54: 208-236, 2004.
5. Winther JF, Kenborg L, Byrne J, Hjorth L, Kaatsch P, Kremer LC, Kuehni CE, Auquier P, Michel G, de Vathaire F, et al: Childhood cancer survivor cohorts in Europe. Acta Oncol 54: 655-668, 2015.
6. Taylor A, Hawkins M, Griffiths A, Davies H, Douglas C, Jenney M, Wallace WH and Levitt G: Long-term follow-up of survivors of childhood cancer in the UK. Pediatr Blood Cancer 42: 161-168, 2004.
7. Konończuk K, Latoch E, Żelazowska-Rutkowska B, Krawczuk-Rybak M and Muszyńska-Rosłan K: Increased levels of adipocyte and epidermal fatty acid-binding proteins in acute lymphoblastic leukemia survivors. J Clin Med 10: 1567, 2021.
8. Armenian SH, Gibson CJ, Rockne RC and Ness KK: Premature aging in young cancer survivors. J Natl Cancer Inst 111: 226-232, 2019.
9. Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, Sklar CA, Robison LL and Oeffinger KC: Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 32: 1218-1227, 2014.
10. Kruseová J, Gottfriedová B, Zichová A, Švojgr K, Hošek P, Lukš A, Kynčl M and Eckschlager T: Is there a higher incidence of sporadic renal angiomyolipoma in childhood cancer survivors? Clin Epidemiol 13: 707-716, 2021.
11. Hudson MM, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, Yeazel M, Recklitis CJ, Marina N, Robison LR, et al: Health status of adult long-term survivors of childhood cancer: A report from the childhood cancer survivor study. JAMA 290: 1583-1592, 2003.
12. van den Berg MH, van Dijk M, Byrne J, Berger C, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, Haupt R, et al: Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: Investigating dose-effect relationships in a European case-control study (PanCareLIFE). Hum Reprod 36: 1561-1573, 2021.

13. Zichová A, Eckschlager T, Ganevová M, Malinová B, Lukš A and Kruseová J: Subsequent neoplasms in childhood cancer survivors. Cancer Epidemiol 68: 101779, 2020.

14. Beekman M, Uh HW, van Heemst D, Wuhrer M, Ruhaak LR, Gonzalez-Covarrubias V, Hankemeier T, Houwing-Duistermaat JJ and Slagboom PE: Classification for longevity potential: The use of novel biomarkers. Front Public Health 4: 233, 2016.

15. De la Fuente M: Role of neuroimmunomodulation in aging. Neuroimmunomodulation 15: 213-223, 2008.

16. Wang S, Prizment A, Thyagarajan B and Blaes A: Cancer treatment-induced accelerated aging in cancer survivors: Biology and assessment. Cancers (Basel) 13: 427, 2021.

17. Stelwagen J, Lubberts S, Steggink LC, Steursma G, Kruyt LM, Donkerbroek JW, van Roon AM, van Gessel AI, van de Zande SC, Meijer C, *et al*: Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy. Br J Cancer 123: 1599-1607, 2020.

18. Zhu J, Wang F, Shi L, Cai H, Zheng Y, Zheng W, Bao P and Shu XO: Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence. Breast Cancer Res Treat 180: 449-459, 2020.

19. Dixon SB, Chen Y, Yasui Y, Pui CH, Hunger SP, Silverman LB, Ness KK, Green DM, Howell RM, Leisenring WM, *et al*: Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. J Clin Oncol 38: 3418-3429, 2020.

20. Bøhn SH, Thorsen L, Kiserud CE, Fosså SD, Lie HC, Loge JH, Wisløff T, Haugnes HS and Reinertsen KV: Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood. Acta Oncol 58: 753-762, 2019.

21. Spathis A, Hatcher H, Booth S, Gibson F, Stone P, Abbas L, Barclay M, Brimicombe J, Thiemann P, McCabe MG, *et al*: Cancer-related fatigue in adolescents and young adults after cancer treatment: Persistent and poorly managed. J Adolesc Young Adult Oncol 6: 489-493, 2017.

22. López-Otín C, Blasco MA, Partridge L, Serrano M and Kroeme G: The hallmarks of aging. Cell 153: 1194-1217, 2013.

23. Kuilman T, Michaloglou C, Mooi WJ and Peeper DS: The essence of senescence. Genes Dev 24: 2463-2479, 2010.

24. Hayflick L and Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 25: 585-621, 1961.

25. Blackburn EH and Szostak JW: The molecular structure of centromeres and telomeres. Annu Rev Biochem 53: 163-194, 1984.

26. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, *et al*: Mutational landscape and significance across 12 major cancer types. Nature 502: 333-339, 2013.

27. Knudsen ES, Nambiar R, Rosario SR, Smiraglia DJ, Goodrich DW and Witkiewicz AK: Pan-cancer molecular analysis of the RB tumor suppressor pathway. Commun Biol 3: 158, 2020.

28. Huan T, Chen G, Liu C, Bhattacharya A, Rong J, Chen BH, Seshadri S, Tanriverdi K, Freedman JE, Larson MG, *et al*: Age-associated microRNA expression in human peripheral blood is associated with all-cause mortality and age-related traits. Aging Cell 17: e12687, 2018.

29. Saul D and Kosinsky RL: Epigenetics of aging and aging-associated diseases. Int J Mol Sci 22: 401, 2021.

30. Vijg J: Somatic mutations, genome mosaicism, cancer and aging. Curr Opin Genet Dev 26: 141-149, 2014.

31. Ness KK, Kirkland JL, Gramatges MM, Wang Z, Kundu M, McCastlain K, Li-Harms X, Zhang J, Tchkonia T, Pluijm SMF and Armstrong GT: Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer. J Clin Oncol 36: 2206-2215, 2018.

32. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, *et al*: Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481-484, 2005.

33. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM and Chan DC: Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141: 280-289, 2010.

34. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, *et al*: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 98: 2043-2051, 2001.

35. Rossi DJ, Jamieson CHM and Weissman IL: Stems cells and the pathways to aging and cancer. Cell 132: 681-696, 2008.

36. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Forsberg EC, *et al*: Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature 512: 198-202, 2014.

37. Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, Dombkowski DM, Cheng T, DePinho RA, Sharpless NE and Scadden DT: Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443: 421-426, 2006.

38. Jaul E and Barron J: Characterizing the heterogeneity of aging: A vision for a staging system for aging. Front Public Health 9: 513557, 2021.

39. Horvath S: DNA methylation age of human tissues and cell types. Genome Biol 14: R115, 2013.

40. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, Klotzle B, Bibikova M, Fan JB, Gao Y, *et al*: Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell 49: 359-367, 2013.

41. Levine ME, Hosgood HD, Chen B, Absher D, Assimes T and Horvath S: DNA methylation age of blood predicts future onset of lung cancer in the women's health initiative. Aging (Albany NY) 7: 690-700, 2015.

42. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, Hou L, Baccarelli AA, Li Y, Stewart JD, *et al*: DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY) 11: 303-327, 2019.

43. Garagnani P, Bacalini MG, Pirazzini C, Gori D, Giuliani C, Mari D, Di Blasio AM, Gentilini D, Vitale G, Collino S, *et al*: Methylation of ELOVL2 gene as a new epigenetic marker of age. Aging Cell 11: 1132-1134, 2012.

44. Zheng Y, Joyce BT, Colicino E, Liu L, Zhang W, Dai Q, Shrubsole MJ, Kibbe WA, Gao T, Zhang Z, *et al*: Blood epigenetic age may predict cancer incidence and mortality. EBioMedicine 5: 68-73, 2016.

45. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, *et al*: An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY) 10: 573-591, 2018.

46. Kresovich JK, Xu Z, O'Brien KM, Weinberg CR, Sandler DP and Taylor JA: Methylation-based biological age and breast cancer risk. J Natl Cancer Inst 111: 1051-1058, 2019.

47. Durso DF, Bacalini MG, Sala C, Pirazzini C, Marasco E, Bonafé M, do Valle ÍF, Gentilini D, Castellani G, Faria AMC, *et al*: Acceleration of leukocytes' epigenetic age as an early tumor and sex-specific marker of breast and colorectal cancer. Oncotarget 8: 23237-23245, 2017.

48. Qin N, Li Z, Song N, Wilson CL, Easton J, Mulder H, Plyler E, Neale G, Walker E, Zhou X, *et al*: Epigenetic age acceleration and chronic health conditions among adult survivors of childhood cancer. J Natl Cancer Inst 113: 597-605, 2021.

49. Johnson AA, Shokhirev MN, Wyss-Coray T and Lehallier B: Systematic review and analysis of human proteomics aging studies unveils a novel proteomic aging clock and identifies key processes that change with age. Aging Res Rev 60: 101070, 2020.

50. Tanaka T, Biancotto A, Moaddel R, Moore AZ, Gonzalez-Freire M, Aon MA, Candia J, Zhang P, Cheung F, Fantoni G, *et al*: Plasma proteomic signature of age in healthy humans. Aging Cell 17: e12799, 2018.

51. Solovev IA, Shaposhnikov MV and Moskalev A: An overview of the molecular and cellular biomarkers of aging. In: Healthy Ageing and Longevity; Springer Nature: Berlin/Heidelberg, Germany, pp67-78, 2019.

52. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, *et al*: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.

53. Hurria A, Jones L and Muss HB: Cancer treatment as an accelerated aging process: Assessment, biomarkers, and interventions. Am Soc Clin Oncol Educ Book 35: e516-e522, 2016.

54. Shen S, Song R, Fuemmeler BF, McGuire KP, Chow WH and Zhao H: Biological aging marker p16INK4a in T cells and breast cancer risk. Cancers (Basel) 12: 3122, 2020.

55. Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, *et al*: Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst 106: dju057, 2014.

56. Smitherman AB, Wood WA, Mitin N, Ayer Miller VL, Deal AM, Davis IJ, Blatt J, Gold SH and Muss HB: Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty. Cancer 126: 4975-4983, 2020.

57. Wood WA, Krishnamurthy J, Mitin N, Torrice C, Parker JS, Snavely AC, Shea TC, Serody JS and Sharpless NE: Chemotherapy and stem cell transplantation increase p16INK4a expression, a biomarker of T-cell aging. EBioMedicine 11: 227-238, 2016.

58. Bourlon MT, Velazquez HE, Hinojosa J, Orozco L, Rios-Corzo R, Lima G, Llorente L, Hernandez-Ramirez DF, Valentin-Cortez FJ, Medina-Rangel I and Atisha-Fregoso Y: Immunosenescence profile and expression of the aging biomarker (p16INK4a) in testicular cancer survivors treated with chemotherapy. BMC Cancer 20: 882, 2020.

59. Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM, Chemaitilly W, Smith WA, Wilson CL, Sklar CA, et al: Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: A report from the St Jude Lifetime cohort study. J Clin Oncol 31: 4496-4503, 2013.

60. Degesys N, Klein C, Binner M, Browner I and Shapiro G: Fitness screening in older cancer patients. J Am Geriatr Soc 59: S141, 2011.

61. Collard RM, Boter H, Schoevers RA and Oude Voshaar RC: Prevalence of frailty in community-dwelling older persons: A systematic review. J Am Geriatr Soc 60: 1487-1492, 2012.

62. Ness KK and Wogksch MD: Frailty and aging in cancer survivors. Transl Res 221: 65-82, 2020.

63. Williams AM, Krull KR, Howell CR, Banerjee P, Brinkman TM, Kaste SC, Partin RE, Srivastava D, Yasui Y, Armstrong GT, et al: Physiologic frailty and neurocognitive decline among young-adult childhood cancer survivors: A prospective study from the St Jude lifetime cohort. J Clin Oncol 39: 3485-3495, 2021.

64. Hayek S, Gibson TM, Leisenring WM, Guida JL, Gramatges MM, Lupo PJ, Howell RM, Oeffinger KC, Bhatia S, Edelstein K, et al: Prevalence and predictors of frailty in childhood cancer survivors and siblings: A report from the childhood cancer survivor study. J Clin Oncol 38: 232-247, 2020.

65. Vatanen A, Hou M, Huang T, Söder O, Jahnukainen T, Kurimo M, Ojala TH, Sarkola T, Turanlahti M, Saarinen-Pihkala UM and Jahnukainen K: Clinical and biological markers of premature aging after autologous SCT in childhood cancer. Bone Marrow Transplant 52: 600-605, 2017.

66. Kruseova J, Vicha A, Feriancikova B and Eckschlager T: Possible mechanisms of subsequent neoplasia development in childhood cancer survivors: A review. Cancers (Basel) 13: 5064, 2021.

67. Wilson CL, Chemaitilly W, Jones KE, Kaste SC, Srivastava DK, Ojha RP, Yasui Y, Pui CH, Robison LL, Hudson MM and Ness KK: Modifiable factors associated with aging phenotypes among adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 34: 2509-2515, 2016.

68. Bennett JA, Winters-Stone KM, Dobek J and Nail LM: Frailty in older breast cancer survivors: Age, prevalence, and associated factors. Oncol Nurs Forum 40: E126-E134, 2013.

69. Smitherman AB, Anderson C, Lund JL, Bensen JT, Rosenstein DL and Nichols HB: Frailty and comorbidities among survivors of adolescent and young adult cancer: A cross-sectional examination of a hospital-based survivorship cohort. J Adolesc Young Adult Oncol 7: 374-383, 2018.

70. Chemaitilly W, Cohen LE, Mostoufi-Moab S, Patterson BC, Simmons JH, Meacham LR, van Santen HM and Sklar CA: Endocrine late effects in childhood cancer survivors. J Clin Oncol 36: 2153-2159, 2018.

71. Lee SJ and Kim NC: Association between sarcopenia and metabolic syndrome in cancer survivors. Cancer Nurs 40: 479-487, 2017.

72. Lee SJ, Park YJ and Cartmell KB: Sarcopenia in cancer survivors is associated with increased cardiovascular disease risk. Support Care Cancer 26: 2313-2321, 2018.

73. Felicetti F, Aimaretti E, Dal Bello F, Gatti F, Godono A, Saba F, Einaudi G, Collino M, Fagioli F, Aragno M and Brignardello E: Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications. Free Radic Biol Med 178: 76-82, 2022.

74. Sadowska-Bartosz I and Bartosz G: Effect of glycation inhibitors on aging and age-related diseases. Mech Ageing Dev 160: 1-18, 2016.

75. Ariffin H, Azanan MS, Abd Ghafar SS, Oh L, Lau KH, Thirunavakarasu T, Sedan A, Ibrahim K, Chan A, Chin TF, et al: Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging. Cancer 123: 4207-4214, 2017.

76. Daniel S, Nylander V, Ingerslev LR, Zhong L, Fabre O, Clifford B, Johnston K, Cohn RJ, Barres R and Simar D: T cell epigenetic remodeling and accelerated epigenetic aging are linked to long-term immune alterations in childhood cancer survivors. Clin Epigenetics 10: 138, 2018.

77. Sulicka-Grodzicka J, Surdacki A, Seweryn M, Mikołajczyk T, Rewiuk K, Guzik T and Grodzicki T: Low-grade chronic inflammation and immune alterations in childhood and adolescent cancer survivors: A contribution to accelerated aging? Cancer Med 10: 1772-1782, 2021.

78. Rossi F, Di Paola A, Pota E, Argenziano M, Di Pinto D, Marrapodi MM, Di Leva C, Di Martino M and Tortora C: Biological aspects of inflamm-aging in childhood cancer survivors. Cancers (Basel) 13: 4933, 2021.

79. Smith WA, Li C, Nottage KA, Mulrooney DA, Armstrong GT, Lanctot JQ, Chemaitilly W, Laver JH, Srivastava DK, Robison LL, et al: Lifestyle and metabolic syndrome in adult survivors of childhood cancer: A report from the St. Jude lifetime cohort study. Cancer 120: 2742-2750, 2014.

80. Clemens E, van der Kooi ALF, Broer L, van Dulmen-den Broeder E, Visscher H, Kremer L, Tissing W, Loonen J, Ronckers CM, Pluijm SMF, et al: The influence of genetic variation on late toxicities in childhood cancer survivors: A review. Crit Rev Oncol Hematol 126: 154-167, 2018.

81. Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, Sklar CA, Stovall M, Yasui Y and Robison LL: Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. J Clin Oncol 22: 3558-3562, 2004.

82. Ravera S, Vigliarolo T, Bruno S, Morandi F, Marimpietri D, Sabatini F, Dagnino M, Petretto A, Bartolucci M, Muraca M, et al: Identification of biochemical and molecular markers of early aging in childhood cancer survivors. Cancers (Basel) 13: 5214, 2021.

83. Su HI, Kwan B, Whitcomb BW, Shliakhsitsava K, Dietz AC, Stark SS, Martinez E, Sluss PM, Sammel MD and Natarajan L: Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH. J Clin Endocrinol Metab 105: 2740-2751, 2020.

84. George SA, Williamson Lewis R, Schirmer DA, Effinger KE, Spencer JB, Mertens AC and Meacham LR: Early detection of ovarian dysfunction by anti-mullerian hormone in adolescent and young adult-aged survivors of childhood cancer. J Adolesc Young Adult Oncol 8: 18-25, 2019.

85. Elchuri SV, Patterson BC, Brown M, Bedient C, Record E, Wasilewski-Masker K, Mertens AC and Meacham LR: Low anti-müllerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy. J Pediatr Adolesc Gynecol 29: 393-399, 2016.

86. de Vet A, Laven JS, de Jong FH, Themmen AP and Fauser BC: Antimüllerian hormone serum levels: A putative marker for ovarian aging. Fertil Steril 77: 357-362, 2002.

87. van Dorp W, van den Heuvel-Eibrink MM, Stolk L, Pieters R, Uitterlinden AG, Visser JA and Laven JS: Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum Reprod 28: 1069-1076, 2013.

88. van der Perk MEM, Broer L, Yasui Y, Robison LL, Hudson MM, Laven JSE, van der Pal HJ, Tissing WJE, Versluys B, Bresters D, et al: Effect of genetic variation in CYP450 on gonadal impairment in a european cohort of female childhood cancer survivors, based on a candidate gene approach: Results from the PanCareLIFE study. Cancers (Basel) 13: 4598, 2021.

89. Salas C, Niembro A, Lozano V, Gallardo E, Molina B, Sánchez S, Ramos S, Carnevale A, Pérez-Vera P, Rivera Luna R and Frias S: Persistent genomic instability in peripheral blood lymphocytes from Hodgkin lymphoma survivors. Environ Mol Mutagen 53: 271-280, 2012.

90. Smith LM, Evans JW, Mori M and Brown JM: The frequency of translocations after treatment for Hodgkin's disease. Int J Radiat Oncol Biol Phys 24: 737-742, 1992.

91. Song N, Li Z, Qin N, Howell CR, Wilson CL, Easton J, Mulder HL, Edmonson MN, Rusch MC, Zhang J, et al: Shortened leukocyte telomere length associates with an increased prevalence of chronic health conditions among survivors of childhood cancer: A report from the St. Jude lifetime cohort. Clin Cancer Res 26: 2362-2371, 2020.

92. Wang J, Van Den Berg D, Hwang AE, Weisenberger D, Triche T, Nathwani BN, Conti DV, Siegmund K, Mack TM, Horvath S and Cozen W: DNA methylation patterns of adult survivors of adolescent/young adult Hodgkin lymphoma compared to their unaffected monozygotic twin. Leuk Lymphoma 60: 1429-1437, 2019.

93. Lipshultz SE, Anderson LM, Miller TL, Gerschenson M, Stevenson KE, Neuberg DS, Franco VI, LiButti DE, Silverman LB, Vrooman LM, *et al*: Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer 22: 946-953, 2016.

94. Krull KR, Hardy KK, Kahalley LS, Schuitema I and Kesler SR: Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. J Clin Oncol 36: 2181-2189, 2018.

95. Armstrong GT, Reddick WE, Petersen RC, Santucci A, Zhang N, Srivastava D, Ogg RJ, Hillenbrand CM, Sabin N, Krasin MJ, *et al*: Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy. J Natl Cancer Inst 105: 899-907, 2013.

96. Krull KR, Sabin ND, Reddick WE, Zhu L, Armstrong GT, Green DM, Arevalo AR, Krasin MJ, Srivastava DK, Robison LL and Hudson MM: Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma. J Clin Oncol 30: 3618-3624, 2012.

97. Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, Fuldner R, Ferrucci L, Gallicchio L, Gavrilov L, *et al*: Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst 111: 1245-1254, 2019.

98. Guida JL, Agurs-Collins T, Ahles TA, Campisi J, Dale W, Demark-Wahnefried W, Dietrich J, Fuldner R, Gallicchio L, Green PA, *et al*: Strategies to prevent or remediate cancer and treatment-related aging. J Natl Cancer Inst 113: 112-122, 2021.

99. van Kalsbeek RJ, van der Pal HJH, Kremer LCM, Bardi E, Brown MC, Effeney R, Winther JF, Follin C, den Hartogh J, Haupt R, *et al*: European PanCareFollowUp recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. Eur J Cancer 154: 316-328, 2021.

100. Trama A, Bernasconi A, Botta L, Byrne J, Grabow D, Reulen RC, Calaminus G and Terenziani M: Late mortality reduction among survivors of germ cell tumors in childhood and adolescence in Europe: A report from the PanCareSurFup cohort. Pediatr Blood Cancer 69: e29991, 2022.

101. Grabow D, Kaiser M, Hjorth L, Byrne J, Alessi D, Allodji RS, Bagnasco F, Bárdi E, Bautz A, Bright CJ, *et al*: The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: A cohort from 12 European countries. Eur J Epidemiol 33: 335-349, 2018.

102. Braam KI, van der Torre P, Takken T, Veening MA, van Dulmen-den Broeder E and Kaspers GJ: Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. Cochrane Database Syst Rev 3: CD008796, 2016.

103. Wiley CD and Campisi J: The metabolic roots of senescence: Mechanisms and opportunities for intervention. Nat Metab 3: 1290-1301, 2021.

104. Lee MB, Hill CM, Bitto A and Kaeberlein M: Antiaging diets: Separating fact from fiction. Science 374: eabe7365, 2021.